paclitaxel

Type: Keyphrase
Name: paclitaxel
First reported 4 hours ago - Updated 4 hours ago - 1 reports

The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent

Paclitaxel (PTX), introduced into the clinic in 1991, has revealed itself as an effective antimicrotubule drug for treatment of a range of otherwise intractable cancers. Along with docetaxel (DTX) and in combination with other agents such as cisplatin, ... [Published Accounts of Chemical Research - 4 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

FDA Grants Priority Review to Bevacizumab (Avastin) for Ovarian Cancer

Approval decision expected in NovemberThe FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab (Avastin, Genentech) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer, and has ... [Published PT Community - 23 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Water-soluble carbon nanotube compositions for drug delivery and medicinal applications

Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are ... [Published Free Patents Online - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Anti-Tumor Drugs Market: Industry Size and Analysis 2019

Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be subcategorized as benign and malignant. Benign is not destructive however, possess a ... [Published MyNewsDesk - Jul 22 2014]
Entities: Tumor, Market, Cancer
First reported Jul 21 2014 - Updated Jul 22 2014 - 1 reports

Genentech's cervical cancer drug receives FDA acceptance for priority review

Genentech, a biotechnology company, has announced FDA acceptance and priority review for the company's supplemental biologics license application, or sBLA, of Avastin plus chemotherapy for the treatment of women with persistent, recurrent or metastatic ... [Published Individual.com - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Induction, chemoradiation regimen effective for stage III/IV head and neck cancers

Induction treatment with cetuximab, paclitaxel and carboplatin, followed by chemoradiation with the same combination, induced high rates of primary site response in patients with stage III or stage IV head and neck squamous cell carcinoma, according to ... [Published Orthopedics Today - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Newer DES Up Survival vs Meds Only in Stable CAD: Analysis

BERN, SWITZERLAND — A new meta-analysis adds some wrinkles to already-complex issues regarding best treatment options for patients with stable CAD [1] . It suggests that medical therapy plus revascularization with PCI using "newer-generation" drug-eluting ... [Published American Journal of Public Health - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Cancer drug available again after company’s licence restored

Supplies of a vital and inexpensive cancer drug will start flowing again from a St. Catharines plant by Friday after the federal drug regulator restored the firm's licence to operate.Biolyse Pharma Corp. had been shut down for almost two months after ... [Published Hamilton Spectator - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Global Ovarian Cancer Therapeutics in Major Developed Markets 2014-2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

Research and Markets (http://www.researchandmarkets.com/research/lj67rg/ovarian_cancer) has announced the addition of the "" report to their offering. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9 billion in 2020 The current ... [Published Individual.com - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer ...

Purpose: Taxanes are a cornerstone treatment in early and advanced stage breast cancer and in other common solid tumor malignancies; however, the development of chemotherapy induced peripheral neuropathy (CIPN) often necessitates dose-reduction, which ... [Published 7thSpace - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

By a News Reporter-Staff News Editor at Clinical Trials Week -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plusREOLYSIN(®) ... [Published 4 Traders - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Boston Scientific receives CE mark for balloon catheter for treatment of PAD

Boston Scientific Corporation, a developer of medical devices, has received CE mark for the Ranger Paclitaxel-Coated PTA balloon catheter for the treatment of peripheral artery disease, or PAD. The technology is now in full European market launch. The ... [Published Individual.com - Jul 16 2014]

Quotes

...According to news reporting from New York City , New York , by NewsRx journalists, research stated, "Sensory neuropathy is a common but difficult to quantify complication encountered during treatment of various cancers with taxane-containing regimens. Docetaxel, paclitaxel, and its nanoparticle albumin-bound formulation have been extensively studied in randomized clinical trials comparing various dose and schedules for the treatment of breast, lung, and ovarian cancers."
...New treatment options are needed," said Sandra Horning, M D , chief medical officer and head of Global Product Development. "We look forward to working with the FDA to bring this potential option to women with this difficult-to-treat cancer as soon as possible."
"While Sorrento's focus will remain on developing our clinical stage assets Cynviloq™ and resiniferatoxin (RTX) as quickly and efficiently as possible, government-sponsored research allows us to explore innovative anti-cancer strategies, such as this potentially first-in-class Myc inhibitor. Our academic collaborators at TSRI and Sorrento's research team will perform the preclinical studies needed to bring this program to an inflection point. We are very grateful for NCI's support of this exciting and potentially paradigm-shifting program" said Henry Ji
...K Vogt, EVP, CSO, & Professor at TSRI, co-discoverer of the Myc, jun, PI3K, & src oncogenes, and Sorrento's collaborator on this project noted that "Myc has also been called the 'emperor of oncogenes'. Targeting Myc with a small molecule inhibitor has been a daunting challenge and has given rise to the current dogma that Myc is 'undruggable'. Numerous studies have strengthened Myc's candidacy as a promising cancer drug target and also suggest that Myc inhibition might be therapeutic in many or most cancer types, irrespective of the underlying driving oncogenic mechanism. This clearly enhances the significance and importance of this potential scientific breakthrough." The scientific details of these Myc inhibitors will be published in a forthcoming manuscript submitted by Dr. Janda, Dr...

More Content

All (283) | News (255) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (4) | Press Releases (3)
sort by: Date | Relevance
Findings from New York University School of Med... [Published HispanicBusiness.com - 1 hour ago]
The Quest for a Simple Bioactive Analog of Pacl... [Published Accounts of Chemical Research - 4 hours ago]
FDA Grants Priority Review to Bevacizumab (Avas... [Published PT Community - 23 hours ago]
FDA Grants Priority Review again to Avastin—for... [Published Oncology Times - Jul 22 2014]
FDA grants Roche's Avastin Priority Review for ... [Published FirstWord Pharma - Jul 22 2014]
Anti-Tumor Drugs Market: Industry Size and Anal... [Published MyNewsDesk - Jul 22 2014]
Water-soluble carbon nanotube compositions for ... [Published Free Patents Online - Jul 22 2014]
ROCHE BEARER SHARE : FDA grants Roche's Avastin... [Published 4 Traders - Jul 22 2014]
FDA Grants Genentech’s Avastin Priority Review ... [Published Town Hall - Jul 22 2014]
AbbVie Acquires Shire To Reincorporate In U.K. [Published Bioresearch Online - Jul 21 2014]
Sorrento Awarded Grant from the National Instit... [Published Benzinga.com - Jul 21 2014]
Sorrento Awarded Grant from the National Instit... [Published BusinessWeek - Jul 21 2014]
Genentech's cervical cancer drug receives FDA a... [Published Individual.com - Jul 21 2014]
Induction, chemoradiation regimen effective for... [Published Orthopedics Today - Jul 21 2014]
Newer DES Up Survival vs Meds Only in Stable CA... [Published American Journal of Public Health - Jul 18 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Cancer drug available again after company’s lic... [Published Hamilton Spectator - Jul 17 2014]
Immunotherapy in Lung Cancer [Published General Medicine eJournal - Jul 17 2014]
Global Ovarian Cancer Therapeutics in Major Dev... [Published Individual.com - Jul 17 2014]
Patent Application Titled "NUCLEIC ACIDS ENCODI... [Published HispanicBusiness.com - Jul 17 2014]
Recent Studies from Nanjing Medical University ... [Published HispanicBusiness.com - Jul 16 2014]
Boston Scientific wins CE mark for 25-mm drug-e... [Published Fierce Drug Delivery - Jul 16 2014]
Chemotherapy dose reduction due to chemotherapy... [Published 7thSpace - Jul 16 2014]
Oncolytics Biotech® Inc. Announces Completion o... [Published 4 Traders - Jul 16 2014]
OncoMed Pharmaceuticals Initiates Randomized Ph... [Published Benzinga.com - Jul 16 2014]
FDA speedy review for new Avastin licence [Published Pharmafocus - Jul 16 2014]
FDA grants priority review for Genentech’s cerv... [Published Pharmaceutical Technology - Jul 16 2014]
Official: Iran Producing 4 High-Quality Nano Drugs [Published Fars News Agency - Jul 16 2014]
Boston Scientific receives CE mark for balloon ... [Published Individual.com - Jul 16 2014]
Forum Post: Tender scalp - is my hair about to ... [Published Macmillan Cancer Support - Jul 16 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Oncolytics Biotech® Inc. Announces Completion o... [Published PR Newswire: Health - Jul 08 2014]
CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics")(TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollmentin a two-arm randomized phase II study of carboplatin, paclitaxel plusREOLYSIN® versus carboplatin and paclitaxel ...
Hanmi Pharmaceuticals and Collaborative Partner... [Published PR Newswire: Health - Jun 30 2014]
BUFFALO, N.Y. and SEOUL, South Korea, June 30, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol - an oral form of the approved drug paclitaxel, ...
AbbVie Announces Initiation of Pivotal Phase II... [Published PR Newswire: Health - Jun 26 2014]
NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and ...
After Chemo, What next? [Published HealthBoards - Jun 19 2014]
My wife, Lorraine (51) has recently completed 6 (3 week cycles) of (palliative) chemotherapy treatment (Paclitaxel and Carboplatin).She has an unknown primary, probably cervical but with no sign or symptoms in this area. Maybe the cancer cleared here ...
Will Gilenya stop pain [Published Multiple Sclerosis Research - Jun 06 2014]
Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL, Salvemini D. The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Oasmia’s Lead Human Product Paclical® Successfu... [Published GlobeNewswire: Acquisitions News - Jun 16 2014]
Oasmia Receives FDA Conditional Approval For It... [Published GlobeNewswire: Acquisitions News - Feb 28 2014]
OncoMed Pharmaceuticals Commences Third Phase 1... [Published GlobeNewswire: Advertising News - Feb 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.